Oxidative Stress Parameters, Trace Elements, and Lipid Profile in Iranian Patients with Gaucher Disease
Gaucher disease (GD) is most frequent disorder of glycolipid storage. The glucosylceramide accumulation might lead to oxidative stress and changes in lipid profile. Regarding the main role of trace elements in hematopoiesis and oxidative stress, this study was aimed to evaluate the zinc and copper levels, three oxidative stress parameters, and lipid profile in GD. Thirty-three patients with GD along with 64 age- and sex-matched healthy controls participated in the study. The levels of zinc and copper were determined using atomic absorption/flame emission spectrophotometer. Malondialdehyde level was measured using HPLC. Total antioxidant capacity (TAC), catalase activity, and lipid profile were assessed using colorimetric methods. Data were analyzed using SPSS software version 16.0. Significant decrease in the serum levels of Zn (p < 0.001) and Cu (p < 0.001) was observed in patients with GD compared to controls. Subjects in control group showed significantly higher levels of TAC than patients with GD (p < 0.001). In contrast, plasma concentration of malondialdehyde was insignificantly higher in patients with GD than controls (p = 0.06). There was a direct correlation between TAC and hemoglobin concentration (p = 0.035; r = 0.369) in patients with GD. Furthermore, the calculated area under receiver operating characteristic curve for HDL cholesterol was equal to 0.938. The results showed that both zinc and copper levels decreased in patients with GD. Patients with GD showed decreased serum content of TAC. It was found that improving the deficiency of zinc and copper by supplementing them could be useful in management of patients with GD.
KeywordsGaucher disease Trace element Oxidative stress Lipid profile
We gratefully acknowledge the supports by Pasteur Institute of Iran. We also thank the staffs of Tarbiat Modares University, Kermanshah University of Medical Sciences, and Mofid Children’s Hospital of Tehran, Iran.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
The study protocol was approved by the Ethics Committee of Pasteur Institute of Iran, and all procedures were in accordance with the ethical standards of the institutional research committee.
- 1.Beutler E, Grabowski GA (2001) Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3635–3668Google Scholar
- 18.Mozafari H, Taghikhani M, Khatami S, Alaei MR, Vaisi-Raygani A, Rahimi Z (2016) Chitotriosidase activity and gene polymorphism in Iranian patients with Gaucher disease and sibling carriers. Iran J Child Neurol 10:62–70Google Scholar
- 24.Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499e502Google Scholar
- 37.Bitla ARKN, Reddy NS, Nagaraju KV et al (2012) Antioxidant status in patients with metabolic syndrome as measured by ferric reducing ability of plasma (FRAP) assay. J Clin Sci Res 3:114–120Google Scholar
- 40.Tabet F, Rye KA (2009) High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) 116:87–98. https://doi.org/10.1042/CS20080106
- 41.Benzie IF, Devaki M (2018) The ferric reducing/antioxidant power (FRAP) assay for non‐enzymatic antioxidant capacity: concepts, procedures, limitations and applications. In: Apak R, Capanoglu E, Shahidi F (eds) Measurement of antioxidant activity & capacity: recent trends and applications. Wiley, New York pp 77–106Google Scholar
- 42.Lemos BS, Medina-Vera I, Blesso CN, Fernandez ML (2018) Intake of 3 eggs per day when compared to a choline bitartrate supplement, downregulates cholesterol synthesis without changing the LDL/HDL ratio. Nutrients 10(2)Google Scholar
- 43.Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, Dagenais GR, Després JP (2001) Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med 161:2685–2692CrossRefGoogle Scholar
- 44.Zimmermann A, Grigorescu-Sido P, Rossmann H, Lackner KJ, Drugan C, al Khzouz C, Bucerzan S, Naşcu I, Zimmermann T, Leucuţa D, Weber MM (2013) Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study. J Inherit Metab Dis 36:555–563CrossRefGoogle Scholar
- 45.de Fost M, Langeveld M, Franssen R, Hutten BA, Groener JEM, de Groot E, Mannens MM, Bikker H, Aerts JMFG, Kastelein JJP, Hollak CEM (2009) Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis 204:267–272CrossRefGoogle Scholar